261 related articles for article (PubMed ID: 15563861)
1. Estrogen and combined estrogen-progestogen therapy in the menopause and breast cancer.
La Vecchia C
Breast; 2004 Dec; 13(6):515-8. PubMed ID: 15563861
[TBL] [Abstract][Full Text] [Related]
2. Postmenopausal hormone therapy: cardiovascular risks.
Prescrire Int; 2003 Apr; 12(64):65-9. PubMed ID: 12674130
[TBL] [Abstract][Full Text] [Related]
3. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin.
Anderson GL; Chlebowski RT; Rossouw JE; Rodabough RJ; McTiernan A; Margolis KL; Aggerwal A; David Curb J; Hendrix SL; Allan Hubbell F; Khandekar J; Lane DS; Lasser N; Lopez AM; Potter J; Ritenbaugh C
Maturitas; 2006 Sep; 55(2):103-15. PubMed ID: 16815651
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer risk with postmenopausal hormonal treatment.
Collins JA; Blake JM; Crosignani PG
Hum Reprod Update; 2005; 11(6):545-60. PubMed ID: 16150813
[TBL] [Abstract][Full Text] [Related]
5. Post-menopausal hormone replacement therapy (cont'd): risk-benefit balance in the hot seat.
Prescrire Int; 2004 Jun; 13(71):106-9. PubMed ID: 15233153
[TBL] [Abstract][Full Text] [Related]
6. Postmenopausal hormone therapy and the risk of breast cancer: the view of an epidemiologist.
Li CI
Maturitas; 2004 Sep; 49(1):44-50. PubMed ID: 15351095
[TBL] [Abstract][Full Text] [Related]
7. Recent epidemiological evidence relevant to the clinical management of the menopause.
Shapiro S
Climacteric; 2007 Oct; 10 Suppl 2():2-15. PubMed ID: 17882666
[TBL] [Abstract][Full Text] [Related]
8. The risk of breast, endometrial and ovarian cancer in users of hormonal preparations.
Bernstein L
Basic Clin Pharmacol Toxicol; 2006 Mar; 98(3):288-96. PubMed ID: 16611204
[TBL] [Abstract][Full Text] [Related]
9. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors.
Holmberg L; Iversen OE; Rudenstam CM; Hammar M; Kumpulainen E; Jaskiewicz J; Jassem J; Dobaczewska D; Fjosne HE; Peralta O; Arriagada R; Holmqvist M; Maenpaa J;
J Natl Cancer Inst; 2008 Apr; 100(7):475-82. PubMed ID: 18364505
[TBL] [Abstract][Full Text] [Related]
10. The breast cancer "plunge" after initial publication of the WHI results: an alternative explanation.
Simon JA; Nahum GG; Stanislaw H; Gaines T
Maturitas; 2010 Jul; 66(3):277-84. PubMed ID: 20471761
[TBL] [Abstract][Full Text] [Related]
11. Postmenopausal hormone therapy and risk of breast cancer.
Chen FP
Chang Gung Med J; 2009; 32(2):140-7. PubMed ID: 19403003
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer risk in the WHI study: the problem of obesity.
Kuhl H
Maturitas; 2005 May; 51(1):83-97. PubMed ID: 15883113
[TBL] [Abstract][Full Text] [Related]
13. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation.
Grodstein F; Manson JE; Stampfer MJ
J Womens Health (Larchmt); 2006; 15(1):35-44. PubMed ID: 16417416
[TBL] [Abstract][Full Text] [Related]
14. New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits.
Modena MG; Sismondi P; Mueck AO; Kuttenn F; Lignières Bd; Verhaeghe J; Foidart JM; Caufriez A; Genazzani AR;
Maturitas; 2005 Sep; 52(1):1-10. PubMed ID: 15963666
[TBL] [Abstract][Full Text] [Related]
15. A comparative review of the risks and benefits of hormone replacement therapy regimens.
Warren MP
Am J Obstet Gynecol; 2004 Apr; 190(4):1141-67. PubMed ID: 15118656
[TBL] [Abstract][Full Text] [Related]
16. Menopausal hormone therapy (HT) in patients with breast cancer.
Batur P; Blixen CE; Moore HC; Thacker HL; Xu M
Maturitas; 2006 Jan; 53(2):123-32. PubMed ID: 16368466
[TBL] [Abstract][Full Text] [Related]
17. Risks of estrogen plus progestin therapy: a sensitivity analysis of findings in the Women's Health Initiative randomized controlled trial.
Shapiro S
Climacteric; 2003 Dec; 6(4):302-10; discussion 310-3. PubMed ID: 15006251
[TBL] [Abstract][Full Text] [Related]
18. Unopposed estrogen therapy and the risk of invasive breast cancer.
Chen WY; Manson JE; Hankinson SE; Rosner B; Holmes MD; Willett WC; Colditz GA
Arch Intern Med; 2006 May; 166(9):1027-32. PubMed ID: 16682578
[TBL] [Abstract][Full Text] [Related]
19. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial.
McTiernan A; Martin CF; Peck JD; Aragaki AK; Chlebowski RT; Pisano ED; Wang CY; Brunner RL; Johnson KC; Manson JE; Lewis CE; Kotchen JM; Hulka BS;
J Natl Cancer Inst; 2005 Sep; 97(18):1366-76. PubMed ID: 16174858
[TBL] [Abstract][Full Text] [Related]
20. Is the estrogen controversy over? Deconstructing the Women's Health Initiative study: a critical evaluation of the evidence.
Harman SM; Naftolin F; Brinton EA; Judelson DR
Ann N Y Acad Sci; 2005 Jun; 1052():43-56. PubMed ID: 16024750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
